A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major

K. E. Burns, H. E. Haysom, A. M. Higgins, N. Waters, R. Tahiri, K. Rushford, T. Dunstan, K. Saxby, Z. Kaplan, S. Chunilal, Z. M. McQuilten, E. M. Wood

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Objectives: To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre. Background: Beta thalassaemia major is a genetic disorder of haemoglobin associated with multiple end-organ complications and typically requiring lifelong RBC transfusion therapy. New therapeutic agents are becoming available based on advances in understanding of the disorder and its consequences. Assessment of the true total cost of transfusion, incorporating both product and activity costs, is required in order to evaluate the benefits and costs of these new therapies. Methods: We describe the bottom-up, time-driven, activity-based costing methodology used to develop process maps to provide a step-by-step outline of the entire transfusion pathway. Detailed flowcharts for each process are described. Direct observations and timing of the process maps document all activities, resources, staff, equipment and consumables in detail. The analysis will include costs associated with performing these processes, including resources and consumables. Sensitivity analyses will be performed to determine the impact of different staffing levels, timings and probabilities associated with performing different tasks. Results: Thirty-one process maps have been developed, with over 600 individual activities requiring multiple timings. These will be used for future detailed cost analyses. Conclusions: Detailed process maps using bottom-up, time-driven, activity-based costing for determining the cost of RBC transfusion in thalassaemia major have been developed. These could be adapted for wider use to understand and compare the costs and complexities of transfusion in other settings.

Original languageEnglish
Pages (from-to)33-40
Number of pages8
JournalTransfusion Medicine
Volume29
Issue number1
DOIs
Publication statusPublished - Feb 2019

Keywords

  • Cost of transfusion
  • Thalassaemia
  • Time-driven activity-based costing

Cite this

@article{be449812cbcd48f7b971e9cd8642dc9b,
title = "A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major",
abstract = "Objectives: To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre. Background: Beta thalassaemia major is a genetic disorder of haemoglobin associated with multiple end-organ complications and typically requiring lifelong RBC transfusion therapy. New therapeutic agents are becoming available based on advances in understanding of the disorder and its consequences. Assessment of the true total cost of transfusion, incorporating both product and activity costs, is required in order to evaluate the benefits and costs of these new therapies. Methods: We describe the bottom-up, time-driven, activity-based costing methodology used to develop process maps to provide a step-by-step outline of the entire transfusion pathway. Detailed flowcharts for each process are described. Direct observations and timing of the process maps document all activities, resources, staff, equipment and consumables in detail. The analysis will include costs associated with performing these processes, including resources and consumables. Sensitivity analyses will be performed to determine the impact of different staffing levels, timings and probabilities associated with performing different tasks. Results: Thirty-one process maps have been developed, with over 600 individual activities requiring multiple timings. These will be used for future detailed cost analyses. Conclusions: Detailed process maps using bottom-up, time-driven, activity-based costing for determining the cost of RBC transfusion in thalassaemia major have been developed. These could be adapted for wider use to understand and compare the costs and complexities of transfusion in other settings.",
keywords = "Cost of transfusion, Thalassaemia, Time-driven activity-based costing",
author = "Burns, {K. E.} and Haysom, {H. E.} and Higgins, {A. M.} and N. Waters and R. Tahiri and K. Rushford and T. Dunstan and K. Saxby and Z. Kaplan and S. Chunilal and McQuilten, {Z. M.} and Wood, {E. M.}",
year = "2019",
month = "2",
doi = "10.1111/tme.12523",
language = "English",
volume = "29",
pages = "33--40",
journal = "Transfusion Medicine",
issn = "0958-7578",
publisher = "Wiley-Blackwell",
number = "1",

}

A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major. / Burns, K. E.; Haysom, H. E.; Higgins, A. M.; Waters, N.; Tahiri, R.; Rushford, K.; Dunstan, T.; Saxby, K.; Kaplan, Z.; Chunilal, S.; McQuilten, Z. M.; Wood, E. M.

In: Transfusion Medicine, Vol. 29, No. 1, 02.2019, p. 33-40.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major

AU - Burns, K. E.

AU - Haysom, H. E.

AU - Higgins, A. M.

AU - Waters, N.

AU - Tahiri, R.

AU - Rushford, K.

AU - Dunstan, T.

AU - Saxby, K.

AU - Kaplan, Z.

AU - Chunilal, S.

AU - McQuilten, Z. M.

AU - Wood, E. M.

PY - 2019/2

Y1 - 2019/2

N2 - Objectives: To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre. Background: Beta thalassaemia major is a genetic disorder of haemoglobin associated with multiple end-organ complications and typically requiring lifelong RBC transfusion therapy. New therapeutic agents are becoming available based on advances in understanding of the disorder and its consequences. Assessment of the true total cost of transfusion, incorporating both product and activity costs, is required in order to evaluate the benefits and costs of these new therapies. Methods: We describe the bottom-up, time-driven, activity-based costing methodology used to develop process maps to provide a step-by-step outline of the entire transfusion pathway. Detailed flowcharts for each process are described. Direct observations and timing of the process maps document all activities, resources, staff, equipment and consumables in detail. The analysis will include costs associated with performing these processes, including resources and consumables. Sensitivity analyses will be performed to determine the impact of different staffing levels, timings and probabilities associated with performing different tasks. Results: Thirty-one process maps have been developed, with over 600 individual activities requiring multiple timings. These will be used for future detailed cost analyses. Conclusions: Detailed process maps using bottom-up, time-driven, activity-based costing for determining the cost of RBC transfusion in thalassaemia major have been developed. These could be adapted for wider use to understand and compare the costs and complexities of transfusion in other settings.

AB - Objectives: To describe the methodology to estimate the total cost of administration of a single unit of red blood cells (RBC) in adults with beta thalassaemia major in an Australian specialist haemoglobinopathy centre. Background: Beta thalassaemia major is a genetic disorder of haemoglobin associated with multiple end-organ complications and typically requiring lifelong RBC transfusion therapy. New therapeutic agents are becoming available based on advances in understanding of the disorder and its consequences. Assessment of the true total cost of transfusion, incorporating both product and activity costs, is required in order to evaluate the benefits and costs of these new therapies. Methods: We describe the bottom-up, time-driven, activity-based costing methodology used to develop process maps to provide a step-by-step outline of the entire transfusion pathway. Detailed flowcharts for each process are described. Direct observations and timing of the process maps document all activities, resources, staff, equipment and consumables in detail. The analysis will include costs associated with performing these processes, including resources and consumables. Sensitivity analyses will be performed to determine the impact of different staffing levels, timings and probabilities associated with performing different tasks. Results: Thirty-one process maps have been developed, with over 600 individual activities requiring multiple timings. These will be used for future detailed cost analyses. Conclusions: Detailed process maps using bottom-up, time-driven, activity-based costing for determining the cost of RBC transfusion in thalassaemia major have been developed. These could be adapted for wider use to understand and compare the costs and complexities of transfusion in other settings.

KW - Cost of transfusion

KW - Thalassaemia

KW - Time-driven activity-based costing

UR - http://www.scopus.com/inward/record.url?scp=85045105955&partnerID=8YFLogxK

U2 - 10.1111/tme.12523

DO - 10.1111/tme.12523

M3 - Article

VL - 29

SP - 33

EP - 40

JO - Transfusion Medicine

JF - Transfusion Medicine

SN - 0958-7578

IS - 1

ER -